Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

CR+CRi rate was defined as the percentage of participants achieving a best response of CR or CRi as assessed by an IRC per iwCLL criteria for tumor response.

CR required all of the following:

• Group A:
• Lymphadenopathy: None > 1.5 centimeters
• Blood Lymphocytes: <4,000/μL
• Hepatomegaly: None
• Splenomegaly: None
• Marrow: Normocellular, < 30% lymphocytes, no B-lymphoid nodules
• Group B:
• Platelet Count: > 100,000/μL
• Hemoglobin: > 11.0 g/dL
• Neutrophils: > 1500/μL

CRi was defined as a CR with peripheral cytopenia and incomplete recovery of the bone marrow, manifested by persistent cytopenias.

ORR was defined as the percentage of participants with a best overall response of CR, CRi, partial remission (PR) or nodular partial remission (nPR) per 2008 iwCLL criteria.

PR required at Least 2 Criteria from Group A AND at least 1 Criterion from Group B:

• Group A:
• Lymphadenopathy: Decrease ≥ 50%
• Blood Lymphocytes: Decrease ≥ 50% from baseline
• Hepatomegaly: Decrease ≥ 50%
• Splenomegaly: Decrease ≥ 50%
• Marrow: 50% reduction in marrow infiltrate or B-lymphoid nodules
• Group B:
• Platelet Count: > 100,000/μL or increase ≥ 50% over baseline
• Hemoglobin: > 11.0 g/dL or increase ≥ 50% over baseline
• Neutrophils: > 1500/μL or increase ≥ 50% over baseline nPR was a response that met the criteria for CR, but the bone marrow biopsy showed lymphoid nodules, reflecting residual disease.

ORR was defined as the percentage of participants with a best overall response of CR, CRi, PR or nPR per 2008 iwCLL criteria.

PFS was defined as the time from the date of first dose of any study drug until the date of disease progression or death due to any cause, whichever occurred first, according to iwCLL criteria. PFS was analyzed using Kaplan-Meier methodology.

PFS was defined as the time from the date of first dose of any study drug until the date of disease progression or death due to any cause, whichever occurred first, according to iwCLL criteria. PFS was analyzed using Kaplan-Meier methodology.

DOR was defined as the time from the first occurrence of overall response (CR, CRi, PR or nPR) until disease progression or death due to any cause, whichever occurred first, as determined by an IRC according to iwCLL criteria.

DOR was defined as the time from the first occurrence of overall response (CR, CRi, PR or nPR) until disease progression or death due to any cause, whichever occurred first, as determined by an IRC according to iwCLL criteria.

OS was defined as the time from the date of the first dose of any study drug until death due to any cause.

TTP was defined as the time from the date of first dose of any study drug until the date of disease progression, as determined by an IRC according to iwCLL criteria.

TTP was defined as the time from the date of first dose of any study drug until the date of disease progression, as determined by an investigator according to iwCLL criteria.